ArticleNeuro-oncology advances
Comparison of epidemiology, treatments, and outcomes in pediatric versus adult ependymoma.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Redefining germline predisposition in children with molecularly characterized ependymoma: a population-based 20-year cohort.Acta neuropathologica communications · 2022Pooled it
- AOSNP-ADAPTR resource level-based recommendations on practical diagnostic strategies for ependymomas.Brain pathology (Zurich, Switzerland) · 2026Article
- Pediatric spinal ependymomas: Long-term surgical outcomes in a cohort of 61 cases.Pediatric investigation · 2026Article
- Two Decades of Childhood Ependymoma Experience at a Tertiary Cancer Center in Turkey.Children (Basel, Switzerland) · 2026Article
- Adult ependymoma: results from the Dutch Brain Tumour Registry on primary treatment and survival.Journal of neuro-oncology · 2025Article
- Nationwide Brain Tumor Registry-based Study of Adult Intracranial Ependymoma in Japan.Neurologia medico-chirurgica · 2025Article
- Individualized therapeutic approaches for relapsed and refractory pediatric ependymomas: a single institution experience.Journal of neuro-oncology · 2025Article
- Review
- Beyond cell-cell contact: therapeutic potential of Eph signaling in central nervous system tumors.Frontiers in molecular neuroscience · 2025Review
- Ependymal Tumors: Overview of the Recent World Health Organization Histopathologic and Genetic Updates with an Imaging Characteristic.AJNR. American journal of neuroradiology · 2024Review
- Fractionated radiotherapy for spinal tumors: A literature review regarding spinal glioma, ependymoma, and meningioma.Neuro-oncology advances · 2024Review
- Conditional survival estimates for ependymomas reveal the dynamic nature of prognostication.Discover oncology · 2024Article
- Article
- Ependymoma from Benign to Highly Aggressive Diseases: A Review.Advances and technical standards in neurosurgery · 2024Review
- Disease characteristics and clinical specific survival prediction of spinal ependymoma: a genetic and population-based study.Frontiers in neurology · 2024Article
- Association Between Urbanicity and Outcomes Among Patients with Spinal Cord Ependymomas in the United States.World neurosurgery · 2024Article
- Pediatric CNS tumors and 2021 WHO classification: what do oncologists need from pathologists?Frontiers in molecular neuroscience · 2024Review
- Profiling spatiotemporal gene expression of the developing human spinal cord and implications for ependymoma origin.Nature neuroscience · 2023Article
- Spinal ependymoma in adults: from molecular advances to new treatment perspectives.Frontiers in oncology · 2023Review
- Ependymomas.Pathologica · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundMounting evidence supports the presence of heterogeneity in the presentation of ependymoma patients with respect to location, histopathology, and behavior between pediatric and adult patients. However, the influence of age on treatment outcomes in ependymoma remains obscure.
methodsThe SEER database years 1975-2016 were queried. Patients with a diagnosis of ependymoma were identified using the International Classification of Diseases for Oncology, Third Edition, coding system. Patients were classified into one of 4 age groups: children (age 0-12 years), adolescents (age 13-21 years), young adults (age 22-45 years), and older adults (age >45 years). The weighed multivariate analysis assessed the impact of age on survival outcomes following surgical treatment.
resultsThere were a total of 6076 patients identified with ependymoma, of which 1111 (18%) were children, 529 (9%) were adolescents, 2039 (34%) were young adults, and 2397 (40%) were older adults. There were statistically significant differences between cohorts with respect to race (
conclusionsOur study using the SEER database demonstrates the various demographic and treatment risk factors that are associated with increased rates of all-cause mortality between the pediatric and adult populations following a diagnosis of ependymoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.